Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2018

  • ID: 4576100
  • Drug Pipelines
  • 50 pages
  • Global Markets Direct
1 of 4
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2018

Summary:

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

The latest report Caspase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
  • The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Report Coverage

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Overview

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Companies Involved in Therapeutics Development

Conatus Pharmaceuticals Inc

New World Laboratories Inc

Novartis AG

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Drug Profiles

ED-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NWL-154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Dormant Products

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Product Development Milestones

Featured News & Press Releases

Apr 30, 2018: Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

Apr 18, 2018: Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

Apr 09, 2018: Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences

Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting

Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Conatus Pharmaceuticals Inc, H1 2018

Pipeline by New World Laboratories Inc, H1 2018

Pipeline by Novartis AG, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Conatus Pharmaceuticals Inc
  • New World Laboratories Inc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll